Improving organ preservation by perfusion through a mesenchymal stromal cell coated bioreactor: a pilot study.
Liver transplantation remains the best available treatment for acute and chronic end stage liver disease. In the era of organ shortage the use of normothermic machine perfusion (NMP) in combination with immunomodulatory strategies driven by mesenchymal stem cell (MSCs) may serve to optimize liver grafts that are currently considered too risky to be transplantable. MSCs activated by licensing factors may downregulate the infiammatory environment of damage liver. In our study we propose to perfuse discharge human and pig liver in a modified NMP by incorporating a MSC-bioreactor.
Since 2004, Prof Cillo is the Director of the Hepatobiliary surgery and Liver transplant Unit at Padova University. His research is focused on clinical and biomolecular features of primary and secondary liver tumors and on innovation in the field of hepatobiliary surgery, organ transplantation with particular reference to transplant oncology and minimally invasive approaches in liver tumors. Prof Cillo is President of the Italian Society of Organ transplantation (SITO) and Councillor of the European Society of Organ transplantation (ESOT). He is author or co-author of more than 300 pubblications with a total IF 1213, H-index 46.
Prof Dazzi’s team focuses on the biology and clinical application of cellular therapies for regenerative medicine. The main interest of the team is to understand the anti-infiammatory properties of mesenchymal stromal cells (MSC) and their interaction with myeloid accessory cells (monocytes and macrophages). Prof Dazzi has already initiated a national clinical programme based on MSC infusions to treat patients with immune-mediated disorders, primarily graft-versus-host disease, autoimmune disease and solid organ transplantation.